Fig 1: Correlations between FNDC5 and tumor immune microenvironment. (A) The association between FNDC5 and different immune cells. (B) Correlation between FNDC5 and T cells CD4 memory activated. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Fig 2: Co-expression module genes associated with FNDC5 were identified using WGCNA. (A) Relationship between scale-free topological model fit and soft threshold (power) in the GSE62254 database. (B) Relationship between average connectivity and various soft thresholds in the GSE62254 database. (C) Dendrogram of modules identified by WGCNA. (D) The top ten genes most associated with FNDC5 expression in GSE62254. (E,F) The (E) KEGG pathway and (F) GO-BP enrichment analysis of these FNDC5-related 1156 genes. ***, p < 0.001.
Fig 3: Irisin inhibited invasion and migration of gastric cancer cells. (A,B) Irisin inhibits migration of (A) Ags and (B) SNU-1 cells. (C,D) Irisin inhibits the invasion of (C) Ags and (D) SNU-1 cells. **, p < 0.01; ***, p < 0.001.
Fig 4: TFs and DNA methylation sites can regulate the expression of FNDC5. (A) Top 20 TFs likely to regulate FNDC5 in different human cancers. (B) TFs with high regulatory potential (10 k distance from TSS) (C) Correlation between FNDC5 and KLF9 mRNA expression in gse62254 database. (D) KLF9 expression in gastric cancer in five mRNA datasets. (E) Correlation analysis of FNDC5 and KLF9 in gastric cancer patients. (F) OS analysis of KLF9 for gastric cancer patients in TCGA database. (G) Association of FNDC5 with DNA methylation in gastric cancer. (H) Association of FNDC5 with methylation site cg00668227. (I) OS analysis of methylation sites (cg00668227) for gastric cancer patients in the TCGA database. *, p < 0.05; ***, p < 0.001.
Fig 5: The effect of FNDC5 on the prognosis for gastric cancer patients. The (A) OS and (B) DFS analysis for FNDC5 in gastric cancer patients in GSE62254.
Supplier Page from Enzo Life Sciences, Inc. for Irisin (human), (recombinant) (active)